Optimization of ultrasound-mediated gene transfer: Comparison of contrast agents and ultrasound modalities

Sorin V. Pislaru, Cristina D Pislaru, Randall R. Kinnick, Ripudamanjit Singh, Rajiv Gulati, James F Greenleaf, Robert D. Simari

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Aims: Ultrasound (US)-enhanced gene transfer for cardiovascular disease is an emerging technique with translational relevance. Prior to pre-clinical applications, optimization of gene transfer using various US contrast agents and parameters is required. In order to do so, two clinically relevant contrast agents (Optison and PESDA), and two US modalities (dedicated continuous wave system and diagnostic scanner) were tested in vitro and in vivo. Methods and Results: In vitro, luciferase activity was measured after exposure of primary vascular cells to combinations of luciferase plasmid, contrast agents, and US exposures. US gene transfer was consistently superior to controls. PESDA was better than Optison; there was no significant difference between US modalities. In vivo, luciferase activity in skeletal muscle of rats was measured after injection of plasmid or adenovirus, expressing luciferase with or without US exposure. Diagnostic US was superior to continuous wave. US plasmid gene transfer was highly localized, and was superior to all controls except adenovirus which lacked spatial specificity. To deliver a secreted transgene product, US gene transfer of a plasmid expressing tissue factor pathway inhibitor (TFPI) to skeletal muscle resulted in a dose-related increase in plasma activity for up to 5 days after delivery. Conclusion: US-enhanced plasmid gene transfer is capable of transducing skeletal muscle in vivo either directly or via an intravascular route. This enhanced nonviral method is an alternative to plasmid DNA alone or viral vectors.

Original languageEnglish (US)
Pages (from-to)1690-1698
Number of pages9
JournalEuropean Heart Journal
Volume24
Issue number18
DOIs
StatePublished - Sep 2003

Fingerprint

Contrast Media
Plasmids
Luciferases
Genes
Skeletal Muscle
Adenoviridae
Transgenes
Blood Vessels
Ultrasonography
Cardiovascular Diseases
Injections
DNA
In Vitro Techniques
FS 069

Keywords

  • Contrast agents
  • Gene transfer
  • Ultrasound

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Optimization of ultrasound-mediated gene transfer : Comparison of contrast agents and ultrasound modalities. / Pislaru, Sorin V.; Pislaru, Cristina D; Kinnick, Randall R.; Singh, Ripudamanjit; Gulati, Rajiv; Greenleaf, James F; Simari, Robert D.

In: European Heart Journal, Vol. 24, No. 18, 09.2003, p. 1690-1698.

Research output: Contribution to journalArticle

Pislaru, Sorin V. ; Pislaru, Cristina D ; Kinnick, Randall R. ; Singh, Ripudamanjit ; Gulati, Rajiv ; Greenleaf, James F ; Simari, Robert D. / Optimization of ultrasound-mediated gene transfer : Comparison of contrast agents and ultrasound modalities. In: European Heart Journal. 2003 ; Vol. 24, No. 18. pp. 1690-1698.
@article{e52c6f2a158b45d9bde88e129888efe3,
title = "Optimization of ultrasound-mediated gene transfer: Comparison of contrast agents and ultrasound modalities",
abstract = "Aims: Ultrasound (US)-enhanced gene transfer for cardiovascular disease is an emerging technique with translational relevance. Prior to pre-clinical applications, optimization of gene transfer using various US contrast agents and parameters is required. In order to do so, two clinically relevant contrast agents (Optison and PESDA), and two US modalities (dedicated continuous wave system and diagnostic scanner) were tested in vitro and in vivo. Methods and Results: In vitro, luciferase activity was measured after exposure of primary vascular cells to combinations of luciferase plasmid, contrast agents, and US exposures. US gene transfer was consistently superior to controls. PESDA was better than Optison; there was no significant difference between US modalities. In vivo, luciferase activity in skeletal muscle of rats was measured after injection of plasmid or adenovirus, expressing luciferase with or without US exposure. Diagnostic US was superior to continuous wave. US plasmid gene transfer was highly localized, and was superior to all controls except adenovirus which lacked spatial specificity. To deliver a secreted transgene product, US gene transfer of a plasmid expressing tissue factor pathway inhibitor (TFPI) to skeletal muscle resulted in a dose-related increase in plasma activity for up to 5 days after delivery. Conclusion: US-enhanced plasmid gene transfer is capable of transducing skeletal muscle in vivo either directly or via an intravascular route. This enhanced nonviral method is an alternative to plasmid DNA alone or viral vectors.",
keywords = "Contrast agents, Gene transfer, Ultrasound",
author = "Pislaru, {Sorin V.} and Pislaru, {Cristina D} and Kinnick, {Randall R.} and Ripudamanjit Singh and Rajiv Gulati and Greenleaf, {James F} and Simari, {Robert D.}",
year = "2003",
month = "9",
doi = "10.1016/S0195-668X(03)00469-X",
language = "English (US)",
volume = "24",
pages = "1690--1698",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "18",

}

TY - JOUR

T1 - Optimization of ultrasound-mediated gene transfer

T2 - Comparison of contrast agents and ultrasound modalities

AU - Pislaru, Sorin V.

AU - Pislaru, Cristina D

AU - Kinnick, Randall R.

AU - Singh, Ripudamanjit

AU - Gulati, Rajiv

AU - Greenleaf, James F

AU - Simari, Robert D.

PY - 2003/9

Y1 - 2003/9

N2 - Aims: Ultrasound (US)-enhanced gene transfer for cardiovascular disease is an emerging technique with translational relevance. Prior to pre-clinical applications, optimization of gene transfer using various US contrast agents and parameters is required. In order to do so, two clinically relevant contrast agents (Optison and PESDA), and two US modalities (dedicated continuous wave system and diagnostic scanner) were tested in vitro and in vivo. Methods and Results: In vitro, luciferase activity was measured after exposure of primary vascular cells to combinations of luciferase plasmid, contrast agents, and US exposures. US gene transfer was consistently superior to controls. PESDA was better than Optison; there was no significant difference between US modalities. In vivo, luciferase activity in skeletal muscle of rats was measured after injection of plasmid or adenovirus, expressing luciferase with or without US exposure. Diagnostic US was superior to continuous wave. US plasmid gene transfer was highly localized, and was superior to all controls except adenovirus which lacked spatial specificity. To deliver a secreted transgene product, US gene transfer of a plasmid expressing tissue factor pathway inhibitor (TFPI) to skeletal muscle resulted in a dose-related increase in plasma activity for up to 5 days after delivery. Conclusion: US-enhanced plasmid gene transfer is capable of transducing skeletal muscle in vivo either directly or via an intravascular route. This enhanced nonviral method is an alternative to plasmid DNA alone or viral vectors.

AB - Aims: Ultrasound (US)-enhanced gene transfer for cardiovascular disease is an emerging technique with translational relevance. Prior to pre-clinical applications, optimization of gene transfer using various US contrast agents and parameters is required. In order to do so, two clinically relevant contrast agents (Optison and PESDA), and two US modalities (dedicated continuous wave system and diagnostic scanner) were tested in vitro and in vivo. Methods and Results: In vitro, luciferase activity was measured after exposure of primary vascular cells to combinations of luciferase plasmid, contrast agents, and US exposures. US gene transfer was consistently superior to controls. PESDA was better than Optison; there was no significant difference between US modalities. In vivo, luciferase activity in skeletal muscle of rats was measured after injection of plasmid or adenovirus, expressing luciferase with or without US exposure. Diagnostic US was superior to continuous wave. US plasmid gene transfer was highly localized, and was superior to all controls except adenovirus which lacked spatial specificity. To deliver a secreted transgene product, US gene transfer of a plasmid expressing tissue factor pathway inhibitor (TFPI) to skeletal muscle resulted in a dose-related increase in plasma activity for up to 5 days after delivery. Conclusion: US-enhanced plasmid gene transfer is capable of transducing skeletal muscle in vivo either directly or via an intravascular route. This enhanced nonviral method is an alternative to plasmid DNA alone or viral vectors.

KW - Contrast agents

KW - Gene transfer

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=0141426729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141426729&partnerID=8YFLogxK

U2 - 10.1016/S0195-668X(03)00469-X

DO - 10.1016/S0195-668X(03)00469-X

M3 - Article

C2 - 14499233

AN - SCOPUS:0141426729

VL - 24

SP - 1690

EP - 1698

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 18

ER -